Community Health Systems, Inc. (CYH) Stock Price & Analysis
Community Health Systems, Inc. (CYH) closed at USD 2.91 on Thursday, October 22, 2026, up 3.19% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 2.82; the Oct 22, 2026 session ranged USD 2.81–2.92 on volume of 1,708,427 shares. Market capitalization is $410.34M, with a 52-week range of USD 2.41–4.43 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 10:07 UTC.
Also available as compact Markdown for AI agents: nexqual.com/CYH.md
Key facts (CYH)
- Last four reported quarters (through Jun 30, 2026): revenue $12.0B, net income $252M (2.1% margin), free cash flow -$185M (SEC filings).
- Valuation: P/E 1.6x (avg 0.8x at the last 1 fiscal year-ends), EV/EBITDA 5.4x, net debt $9.40B.
- Insider open-market sales, last ~7 months: 1 Form 4 filings, $118K; 1 not under a Rule 10b5-1 plan ($118K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Hold (mean 3.20 on a 1–5 scale) (10 analysts), mean target USD 3.09 (range 2–4).
- Total return with dividends: 1Y -10.7% vs S&P 500 +14.9%; 5Y -74.3% vs S&P 500 +80.3%.
- Next earnings: 2026-10-28, EPS estimate USD -0.32, revenue estimate $2.80B.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (CYH)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $12.4B | $12.2B | $12.5B | $12.6B | $12.5B | $12.0B |
| Gross profit | $10.3B | $10.2B | $10.5B | $10.7B | $10.6B | — |
| Operating income | $1.40B | $821M | $957M | $542M | $1.49B | $1.36B |
| Net income | $230M | $46.0M | -$133M | -$516M | $509M | $252M |
| EPS (diluted) | $1.76 | $0.35 | -$1.02 | -$3.90 | $3.77 | — |
| Free cash flow | -$600M | -$115M | -$257M | $120M | $208M | -$185M |
| Gross margin | 83.5% | 83.8% | 84.0% | 84.6% | 85.1% | — |
| Operating margin | 11.3% | 6.7% | 7.7% | 4.3% | 11.9% | 11.4% |
| Net margin | 1.9% | 0.4% | -1.1% | -4.1% | 4.1% | 2.1% |
| Revenue growth | +4.9% | -1.3% | +2.3% | +1.2% | -1.2% | — |
| Cash + short-term investments | $507M | $118M | $38.0M | $37.0M | $260M | — |
| Total debt | $12.1B | $11.6B | $11.5B | $11.5B | $10.4B | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (CYH)
P/E 1.6x · P/S 0.0x · EV/EBITDA 5.4x · EV/Sales 0.8x · FCF yield -45.08% · Earnings yield 61.41% · Net debt $9.40B · EV $9.81B
P/E at fiscal year-ends: Dec 2025 0.8x.
Insider sales (SEC Form 4, open-market, last ~7 months) (CYH)
0 of 1 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-08-25 | Jennings William Norris | Director | 40,000 | $118K | 51% | No | Too little history (no open-market trades in 2023–2025) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (CYH)
Consensus Hold (mean 3.20 on a 1–5 scale), 10 analysts; mean target USD 3.09 (low 2, high 4).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-23 | BMO Capital | Initiated | Market Perform | $3 |
| 2026-07-27 | RBC Capital | Target lowered | Outperform | $5 → $4 |
| 2026-07-27 | Truist Securities | Target lowered | Hold | $3.75 → $3.25 |
| 2026-07-25 | UBS | Target lowered | Neutral | $3.2 → $3 |
| 2026-07-23 | Barclays | Target lowered | Underweight | $3 → $2.5 |
| 2026-07-14 | Truist Securities | Target raised | Hold | $3 → $3.75 |
| 2026-07-08 | Barclays | Downgrade | Equal-Weight → Underweight | $3 |
Total return (dividends reinvested) (CYH)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | -10.7% | -74.3% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | -10.8% | -23.7% |
| Volatility (annualized) | 55.8% | 80.5% |
| Max drawdown | -43.5% (Oct 2025→Apr 2026) | -86.1% (Nov 2021→Oct 2022) |
CYH suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Partner | HealthTrust Purchasing Group | “We have a noncontrolling ownership interest in and participation agreement with HealthTrust Purchasing Group, L.P., or HealthTrust, a group purchasing organization, or GPO, which benefits members through scaled pricing.” |
Quoted from the company's 10-K filed Feb 19, 2026.
CYH analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.32 | $-0.01 | +2471.5% | $2.80B | 5 |
| Next quarter (ends Dec 2026) | $-0.17 | $0.18 | -196.0% | $2.86B | 6 |
| Current fiscal year (ends Dec 2026) | $-1.17 | $-0.58 | +102.7% | $11.45B | 5 |
| Next fiscal year (ends Dec 2027) | $-0.52 | $0.11 | -571.8% | $11.53B | 7 |
Key Statistics (as of October 23, 2026 at 10:07 UTC)
| Price | USD 2.91 |
|---|---|
| Change | ▲ 3.19% (up) |
| Previous Close | USD 2.82 |
| Open | USD 2.81 |
| Day Range | USD 2.81 – 2.92 |
| 52-Week Range | USD 2.41 – 4.43 |
| Volume | 1,708,427 shares |
| Market Cap | $410.34M |
| Exchange | NYQ |
Technical Analysis (CYH)
Nexqual's technical model rates CYH "BUY" based on 4 bullish and 1 bearish signals across 127 daily candles, as of October 23, 2026 at 10:07 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 53.19 (neutral) |
| vs SMA50 | Above (USD 2.9) |
| MACD | -0.01 (negative) |
Analyst Ratings (CYH)
Wall Street analysts rate CYH "Hold" based on 10 analysts, with a mean price target of USD 3.09 (range USD 2–4), per Nexqual as of October 23, 2026 at 10:07 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 10 |
| Mean Target | USD 3.09 |
| High Target | USD 4 |
| Low Target | USD 2 |
| Buy / Hold / Sell | 2 / 5 / 3 |
Earnings (CYH)
| Next Earnings Date | 2026-10-28 |
|---|---|
| EPS Estimate | USD -0.32 |
| Revenue Estimate | $2.80B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.19 vs est -0.1 ▼ miss |
| 2026-03-31 | USD -0.48 vs est -0.09 ▼ miss |
| 2025-12-31 | USD 0 vs est -0.2 ▲ beat |
| 2025-09-30 | USD 1.27 vs est -0.28 ▲ beat |
Source: Nexqual, October 23, 2026 at 10:07 UTC.
Financials & Fundamentals (CYH)
| Total Revenue | $11.98B |
|---|---|
| Revenue Growth (latest quarter, YoY) | -9.80% |
| Gross Margin | +41.41% |
| Operating Margin | +7.68% |
| Profit Margin | +2.10% |
| Current Ratio | 1.53 |
| Total Cash | $149.00M |
| Total Debt | $10.20B |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | -$185.00M (-1.5% of revenue) |
Source: Nexqual, October 23, 2026 at 10:07 UTC.
Financial Health Score (CYH)
Nexqual rates Community Health Systems, Inc.'s overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 10:07 UTC.
| Growth | Weak — Revenue -1% YoY (annual), declining |
|---|---|
| Profitability | Strong — Gross margin 41%, operating 8% (last 12 months) |
| Balance Sheet | Mixed — $149M cash and investments vs $9.55B debt (Jun 2026, SEC) |
| Cash Flow | Weak — FCF negative: -$185M (last 4 quarters to Jun 2026, SEC), burning cash |
| Efficiency | Mixed — No data |
Ownership (CYH)
| Insider Ownership | +15.18% |
|---|---|
| Institutional Ownership | +83.95% |
| Shares Outstanding | 141.01M |
| Float | 82.95M |
| Short % of Float | +9.49% |
Source: Nexqual, October 23, 2026 at 10:07 UTC.
Leadership (CYH)
Community Health Systems, Inc. is led by Kevin J. Hammons, President, CEO & Director, per Nexqual as of October 23, 2026 at 10:07 UTC.
| President, CEO & Director | Kevin J. Hammons |
|---|---|
| CFO & Executive VP | Jason K. Johnson |
| Executive Vice President of Operations & Development | Kevin A. Stockton |
| President of Region 3 Operations | Mark B. Medley |
| President of Region 2 Operations | Chad A. Campbell |
Major Backers & Investors (CYH)
Notable institutional backers of Community Health Systems, Inc. include Castleknight Management LP, Apollo Management Holdings, L.P., Eversept Partners, LP, according to Nexqual as of October 23, 2026 at 10:07 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Castleknight Management LP | 9.49% |
| Apollo Management Holdings, L.P. | 8.41% |
| Eversept Partners, LP | 5.58% |
| Nomura Holdings Inc. | 4.75% |
| Whitebox Advisors, LLC | 2.65% |
| Fidelity | 1.01% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 7.75% |
| Vanguard Group | 5.89% |
| Geode Capital | 2.25% |
| State Street | 2.17% |
Source: Nexqual, October 23, 2026 at 10:07 UTC.
From Community Health Systems, Inc.'s Latest SEC 10-K Filing (filed 2026-02-19)
Key Strengths & Strategy (as disclosed to the SEC)
- When expanding services—in both the acute and non-acute care settings—our approach is data-driven and strategic to ensure our investments are responsive to community and patient needs and produce sound financial results.
Partnerships
- We have a noncontrolling ownership interest in and participation agreement with HealthTrust Purchasing Group, L.P., or HealthTrust, a group purchasing organization, or GPO, which benefits members through scaled pricing.
- In a number of our markets, we have partnered with local physicians, for-profit entities and/or not-for-profit providers in the ownership of our facilities.
Legal & Regulatory Risks (Item 1A, quoted)
- We could be subject to substantial uninsured liabilities or increased insurance costs as a result of significant legal actions.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| INNV | InnovAge Holding Corp. | USD 9.52 | ▲ 4.16% |
| USPH | U.S. Physical Therapy, Inc. | USD 88.73 | ▲ 2.84% |
| NUTX | Nutex Health Inc. | USD 206.09 | ▲ 4.29% |
| PNTG | The Pennant Group, Inc. | USD 42.23 | ▲ 2.9% |
| AGL | agilon health, inc. | USD 90.29 | ▼ 0.77% |
| CMPS | COMPASS Pathways Plc - American | USD 11.63 | ▼ 1.77% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 10:07 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt